Toyama Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Toyama Japan (1936)
Status: Acquired by Taisho Toyama Pharmaceutical Ltd. (2002) → now Fujifilm (2008)

Organization Overview

First Clinical Trial
2008
NCT00663936
First Marketed Drug
1981
piperacillin (pipracil)
First NDA Approval
1981
piperacillin (pipracil)
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

FUJIFILM Toyama Chemical Co., Ltd. | Toyama Chemical Co., Ltd.

Active Ingredients

Marketed Drugs (1)

piperacillin (pipracil) (1981 NDA)

Drugs in Phase 3 Trials (6)

azithromycin (zithromax) (1 trial)

favipiravir (2 trials)

human autologous synovial stem cells (1 trial)

hydroxychloroquine (plaquenil) (1 trial)

t-614 (1 trial)

zinc sulfate (1 trial)

Drugs in Phase 2 Trials (1)

Edonerpic (4 trials)

Indications

Approved Indications


 

Intraabdominal Infections

Pelvic Infection

Pneumonia, Bacterial

Skin Diseases, Infectious

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Arthritis (Phase 3)

Arthritis, Rheumatoid (Phase 3)

Cognitive Dysfunction (Phase 2)

Coronavirus Infections (Phase 3)

Liver Diseases (Phase 1)

Severe Acute Respiratory Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 7